KDR and renal cell carcinoma: Arresting VEGFR2 on the cell surface through trans complex formation with NRP1 may also enhance efficient targeting of VEGFR2 using anti‐angiogenic therapy through slower turn‐over of the receptor; this scenario warrants further testing in mechanistic studies involving murine models of RCC.